Experience of the Institut Gustave-Roussy in Alternating Radiotherapy and Chemotherapy Schedules as Induction Treatment in Limited Small-Cell Lung Cancer

2015 ◽  
pp. 190-193 ◽  
Author(s):  
T. Le Chevalier ◽  
R. Arriagada ◽  
F. Thomas ◽  
P. Baldeyrou ◽  
P. Ruffie ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Induction Treatment ◽  
Small Cell Lung

Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group.

1993 ◽  
Vol 11 (5) ◽  
pp. 879-884 ◽  
Author(s):  
D H Johnson ◽  
A T Turrisi ◽  
A Y Chang ◽  
R Blum ◽  
P Bonomi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pilot Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Eastern Cooperative Oncology Group ◽  
Small Cell ◽  
Induction Treatment ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Limited Stage

PURPOSE This pilot study was undertaken to determine the efficacy and feasibility of alternating cisplatin and etoposide with multiple daily fractions of thoracic radiotherapy (TRT) in patients with limited-stage small-cell lung cancer (SCLC). PATIENTS AND METHODS Thirty-four SCLC patients received four courses of cisplatin (30 mg/m2/d x 3) plus etoposide (120 mg/m2/d x 3) (PE) every 3 weeks. TRT was administered twice daily (1.5 Gy per fraction) for 5 consecutive days in the week after cycles 1, 2, and 3 of chemotherapy (total TRT dose, 45 Gy). Patients who achieved a complete response (CR) received one course of late-intensification (LI) treatment consisting of cyclophosphamide (4 g/m2) and etoposide (900 mg/m2). Prophylactic cranial irradiation (PCI) was optional. RESULTS Nineteen of 32 assessable patients achieved a CR (59%) and 12 had a partial response (38%), for an overall response rate of 97% (95% confidence interval [CI], 84% to 99%). Median survival was 18 months, while 2-year progression-free survival was 47%. Leukopenia < or = 1,000/microL occurred in 12% of induction treatment cycles. Severe esophagitis was uncommon. Pulmonary fibrosis that was asymptomatic or minimally symptomatic was observed in eight patients (25%). There was one episode of adult respiratory distress syndrome (ARDS) during LI chemotherapy. Life-threatening neutropenia (< or = 500/microL) developed in all patients who underwent LI chemotherapy, with a median duration of 10 days (range, 8 to 19). Two patients died of sepsis during LI chemotherapy. CONCLUSION Alternating PE and TRT as performed in this trial is an effective brief induction regimen for limited-stage SCLC. However, this particular regimen did not appear to be substantially different in terms of efficacy or toxicity compared with regimens using concurrent chemotherapy and standard-fraction TRT. LI chemotherapy was associated with unacceptable toxicity and did not appear to have a favorable impact on survival.

scholarly journals Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer

2017 ◽  
Vol 13 (3) ◽  
pp. 1647-1654 ◽  
Author(s):  
Magda Palka ◽  
Antonio Sanchez ◽  
Mar Córdoba ◽  
Gema Díaz Nuevo ◽  
Andrés Varela De Ugarte ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Induction Treatment ◽  
Small Cell Lung ◽  
Stage Iiia
Sign in / Sign up

Export Citation Format

Share Document